Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study.

Authors

Ravi N. Samy MD, Lehigh Valley Health NetworkFollow
Brian R Earl
Noga Lipschitz
Ivy Schweinzger
Mark Currier
Timothy Cripe

Publication/Presentation Date

10-1-2019

Abstract

OBJECTIVE: Determine if oncolytic herpes simplex virus (oHSV) can eradicate cholesteatoma (CHST) in a gerbil model.

METHODS: An in vivo model of CHST was developed in Mongolian gerbils by combining

RESULTS: The

CONCLUSIONS:

LEVEL OF EVIDENCE: NA.

Volume

4

Issue

5

First Page

532

Last Page

542

ISSN

2378-8038

Published In/Presented At

Samy, R. N., Earl, B. R., Lipschitz, N., Schweinzger, I., Currier, M., & Cripe, T. (2019). Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study. Laryngoscope investigative otolaryngology, 4(5), 532–542. https://doi.org/10.1002/lio2.307

Disciplines

Medicine and Health Sciences

PubMedID

31637298

Department(s)

Department of Surgery, Division of Otolaryngology

Document Type

Article